Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of care/Placebo Clear all
Completed Phase 2 Interventional

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

NCT04600089
View directory record Official record
Conditions
Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm
Interventions
Saline, Ketamine
Drug
Lead sponsor
Eric Johnson
Other
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

NCT04149574
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
nivolumab, Placebo, Bacillus Calmette-Guérin (BCG)
Drug · Other · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 4 Interventional

Quality of Life and Nutritional Improvements in Cirrhotic Patients

NCT01842113
View directory record Official record
Conditions
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions
Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina

NCT01508910
View directory record Official record
Conditions
Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
Interventions
Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
Biological · Other
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
41
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Collagen Bupivacaine Implant in Women Following Abdominal Hysterectomy

NCT00624910
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bupivacaine Collagen Sponge (CollaRx®), placebo
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 3, 2026, 7:55 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

NCT07161843
View directory record Official record
Conditions
Acute Renal Failure (ARF), Acute Tubular Necrosis
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
10 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rosharon, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01493531
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
88
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04718103
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
41
States / cities
Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 2Phase 3 Interventional

Nebulised Heparin in Patients With Severe COVID-19

NCT04545541
View directory record Official record
Conditions
Covid19, Respiratory Failure
Interventions
Nebulised unfractionated heparin (UFH)
Drug
Lead sponsor
Australian National University
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 3, 2026, 7:55 PM EDT
Recruiting Phase 2 Interventional

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

NCT05268289
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Fontana, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 3, 2026, 7:55 PM EDT
Recruiting Phase 2 Interventional

Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis

NCT06207370
View directory record Official record
Conditions
Babesiosis
Interventions
Tafenoquine, Placebo
Drug · Other
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 3, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Interventions
Gabapentin, Placebo, Chemotheraphy, Radiation Therapy, Analgesic Agent, Biospecimen Collection, Survey Administration
Drug · Radiation · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
212
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 171 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 4 Interventional

Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks

NCT00875862
View directory record Official record
Conditions
Adhesive Capsulitis, Post-operative Pain
Interventions
Interscalene catheter with Ropivicaine or normal saline
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 3, 2026, 7:55 PM EDT
Not listed Phase 4 Interventional

The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade

NCT02005575
View directory record Official record
Conditions
Post Minimally Invasive Thorascopic Surgical Pain
Interventions
Bupivacaine and Dexamethasone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 3 Interventional

Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke

NCT01098981
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
Device · Drug
Lead sponsor
Cerevast Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 3, 2026, 7:55 PM EDT
Active, not recruiting Early Phase 1 Interventional

Vaginal Microbiome Exposure and Immune Responses in C-section Infants

NCT03567707
View directory record Official record
Conditions
Allergic Diseases, Asthma
Interventions
Vaginal seeding, Placebo Seeding, Standard care, Post-seeding Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional Results available

Etanercept for the Treatment of Lupus Nephritis

NCT00447265
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Etanercept, Lupus Treatment- Standard of Care, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 3, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

NCT05891496
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sun City, Arizona • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Nipocalimab, Placebo, Standard of care treatment
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
38
States / cities
Beverly Hills, California • Fullerton, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 3, 2026, 7:55 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

NCT03381196
View directory record Official record
Conditions
Influenza A
Interventions
Pimodivir 600 mg, Placebo, SOC Treatment
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
13 Years to 85 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 3, 2026, 7:55 PM EDT